189 related articles for article (PubMed ID: 9626479)
1. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model.
Vail DM; Chun R; Thamm DH; Garrett LD; Cooley AJ; Obradovich JE
Clin Cancer Res; 1998 Jun; 4(6):1567-71. PubMed ID: 9626479
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma.
Khanna C; Lund EM; Redic KA; Hayden DW; Bell FW; Goulland EL; Klausner JS
J Am Vet Med Assoc; 1998 Oct; 213(7):985-90. PubMed ID: 9776993
[TBL] [Abstract][Full Text] [Related]
3. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors.
Vail DM; Kravis LD; Cooley AJ; Chun R; MacEwen EG
Cancer Chemother Pharmacol; 1997; 39(5):410-6. PubMed ID: 9054954
[TBL] [Abstract][Full Text] [Related]
4. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
Working PK; Newman MS; Sullivan T; Yarrington J
J Pharmacol Exp Ther; 1999 May; 289(2):1128-33. PubMed ID: 10215696
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma.
Simon D; Moreno SN; Hirschberger J; Moritz A; Kohn B; Neumann S; Jurina K; Scharvogel S; Schwedes C; Reinacher M; Beyerbach M; Nolte I
J Am Vet Med Assoc; 2008 Mar; 232(6):879-85. PubMed ID: 18341445
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients.
von Gruenigen V; Frasure H; Fusco N; DeBernardo R; Eldermire E; Eaton S; Waggoner S
Cancer; 2010 Oct; 116(20):4735-43. PubMed ID: 20629022
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
Rose PG
Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
Lyass O; Hubert A; Gabizon AA
Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma.
Teske E; Rutteman GR; Kirpenstein J; Hirschberger J
Vet Comp Oncol; 2011 Dec; 9(4):283-9. PubMed ID: 22077409
[TBL] [Abstract][Full Text] [Related]
11. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin.
Valerius KD; Ogilvie GK; Fettman MJ; Walton JA; Richardson K; Powers BE; McNiel EA; Rogers QR
J Am Vet Med Assoc; 1999 Feb; 214(3):353-6. PubMed ID: 10023395
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
14. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies.
Drake RD; Lin WM; King M; Farrar D; Miller DS; Coleman RL
Gynecol Oncol; 2004 Aug; 94(2):320-4. PubMed ID: 15297168
[TBL] [Abstract][Full Text] [Related]
15. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma.
Rusk A; Cozzi E; Stebbins M; Vail D; Graham J; Valli V; Henkin J; Sharpee R; Khanna C
Clin Cancer Res; 2006 Dec; 12(24):7456-64. PubMed ID: 17189419
[TBL] [Abstract][Full Text] [Related]
16. Direct injection of liposome-encapsulated doxorubicin optimizes chemomyectomy in rabbit eyelid.
McLoon LK; Wirtschafter JD
Invest Ophthalmol Vis Sci; 1999 Oct; 40(11):2561-7. PubMed ID: 10509650
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of outcome associated with subcutaneous and intramuscular hemangiosarcoma treated with adjuvant doxorubicin in dogs: 21 cases (2001-2006).
Bulakowski EJ; Philibert JC; Siegel S; Clifford CA; Risbon R; Zivin K; Cronin KL
J Am Vet Med Assoc; 2008 Jul; 233(1):122-8. PubMed ID: 18593321
[TBL] [Abstract][Full Text] [Related]
18. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer.
Rivera E; Valero V; Esteva FJ; Syrewicz L; Cristofanilli M; Rahman Z; Booser DJ; Hortobagyi GN
Cancer Chemother Pharmacol; 2002 Apr; 49(4):299-302. PubMed ID: 11914909
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
